Navigation Links
/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/
Date:9/2/2008

CALGARY, Sept. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that following U.S. Food and Drug Administration (FDA) review, the Company is initiating a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with K-RAS or EGFR-activated tumours. The Principal Investigator is Dr. Miguel Villalona-Calero, Professor Division of Hematology/Oncology and Department of Internal Medicine and Pharmacology at The Ohio State University Comprehensive Cancer Center.

"In this era of personalized cancer treatment, we are quite excited about this trial," said Dr. Villalona-Calero. "Although we have had for some time treatments that target EGFR, K-RAS has been an elusive target. REOLYSIN(R) has the potential to target K-RAS activated tumors, possibly enhancing the beneficial effects produced by chemotherapy."

"This trial gives Oncolytics the opportunity to treat NSCLC patients in a first-line clinical setting," said Dr. Brad Thompson, President and CEO of Oncolytics. "Assuming we achieve an acceptable response rate, the combination of REOLYSIN(R) with paclitaxel and carboplatin for NSCLC would be a strong candidate for registration studies."

This trial is a single arm, two-stage, open-label, Phase 2 study of REOLYSIN(R) given intravenously with paclitaxel and carboplatin every 3 weeks. Patients will receive four to six cycles of paclitaxel and carboplatin in conjunction with REOLYSIN(R), at which time REOLYSIN(R) may be continued as a monotherapy. It is anticipated that up to 36 patients will be treated in this trial.

Eligible patients include those with metastatic or recurrent NSCLC with K-RAS or EGFR-activated tumours, who have not received chemotherapy treatment for their metastatic or recurrent disease. Patients must have demonstrated mutations in K-RAS or EGFR, or EGFR
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
2. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
3. Oncolytics Biotech Inc. Announces 2008 Second Quarter Results
4. Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies with REOLYSIN(R)
5. Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
6. Oncolytics Biotech Inc. to Present at BIO 2008 International Convention
7. Oncolytics Biotech Inc. Announces Start of Enrolment in Phase 1/2 Ovarian Cancer Clinical Trial with REOLYSIN(R)
8. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
9. Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
10. Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at ASGT Meeting
11. Oncolytics Biotech Inc. Announces Issuance of 9th Canadian Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014 Research and ... "Global and China Gel Permeation Chromatography (GPC) Industry Report ... The Global and China Gel Permeation Chromatography (GPC) Industry ... current state of the global gel permeation chromatography industry ... report provides a basic overview of the industry including ...
(Date:8/22/2014)... 22, 2014 The identification of ... can be accelerated by exome sequencing. Built on ... the custom SeqCap EZ Developer system has been ... Watson will additionally present how he achieved coverage ... human and mouse exome kits. With over 236,000 ...
(Date:8/21/2014)... group at the Institute for Molecular Medicine Finland ... has developed a novel "man and machine" decision ... diagnostic aid was described in PLOS One ... is based on computer vision algorithms similar to ... visualization of only the diagnostically most relevant areas. ...
(Date:8/21/2014)... His Majesty Willem-Alexander, King of the ... of His Majesty Willem-Alexander, King of the Netherlands, has ... of POET-DSM Advanced Biofuels’ Project LIBERTY cellulosic ethanol plant ... King will take part in the Grand Opening Ceremony ... a.m.-12:20 p.m. and tour the plant. POET-DSM is a ...
Breaking Biology Technology:Global and China Gel Permeation Chromatography (GPC) Industry Report 2014 2Efficient Identification of Protein-Coding Variants in a Model Organism Through Exome Sequencing, New Webinar Hosted by Xtalks 2A novel 'man and machine' decision support system makes malaria diagnostics more effective 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3
... VisEn Medical Inc., a leader in fluorescence in vivo ... of its new Cat-K FAST (TM) ... with disease progression and therapeutic response in vivo . ... therapeutic target in a range of bone-related diseases, including cancer metastasis ...
... 7 Mylan Inc. (Nasdaq: MYL ) today ... from the U.S. Food and Drug Administration (FDA) for its ... , , Bicalutamide Tablets are the generic version of ... of approximately $322 million for the 12 months ending March ...
... MATEO, Calif., July 7 King Pharmaceuticals, Inc. (NYSE: ... today announced that on July 2, 2009, King met with the ... Letter regarding the New Drug Application (NDA) for REMOXY(R). The ... to resubmit the REMOXY(R) NDA and to address all FDA comments ...
Cached Biology Technology:VisEn Launches New Cat-K FAST(TM) Fluorescence Molecular Imaging Agent 2King and Pain Therapeutics Announce REMOXY(R) NDA Update 2King and Pain Therapeutics Announce REMOXY(R) NDA Update 3
(Date:8/21/2014)... unknown process for harvesting energy and producing oxygen from ... University scientist has discovered. The discovery lays the foundation ... energy from the Sun, and understanding dense blooms like ... worldwide. A paper describing the discovery will be published ... journal Science on 21 August 2014. , ...
(Date:8/21/2014)... aimed at improving the food intake, health and quality ... is among three projects at the University of Waterloo ... Canadian Institutes of Health Research (CIHR). , Professor ... at Waterloo, and a Schlegel research chair in nutrition ... investigate why many Canadians living in long-term care homes ...
(Date:8/21/2014)... Ever heard of the water window? It consists of ... are not absorbed by the water in biological tissues. ... develop coherent radiations within the water window. These could ... a high-contrast image of the biological samples or to ... study identifies the physical mechanism needed to efficiently generate ...
Breaking Biology News(10 mins):Hot-spring bacteria reveal ability to use far-red light for photosynthesis 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 3Grants will fund landmark aging research at Waterloo 2Water window imaging opportunity 2
... to be satisfied? Less than half as much as ... snacking study. Using chocolate chips, apple pie, and potato ... Wansink designed a study to determine if people who ... hungrier or satisfied fifteen minutes after eating., ,Two groups ...
... in the American Chemical Society,s (ACS,) award-winning Global ... to improve the sensitivity of the test often used to ... possessions of passengers at airport security screening stations. Based ... ACS, The Journal of Physical Chemistry C , the ...
... Aviv Prof. Nathan Nelson of Tel Aviv University,s ... Center has been awarded the 2012 Israel Prize in ... awarded in Jerusalem on the eve of Israel,s Independence ... and molecular biology, Prof. Nelson is internationally renowned for ...
Cached Biology News:New American Chemical Society podcast: Boosting the sensitivity of airport security screening 2
Practical tool for easy, effective sealing of 0.2ml PCR tubes and plates using cap strips....
... by BioLegend, the Quansys Biosciences Q-Plex Array ... of cytokines/chemokines for human, mouse, and rat ... a fully quantitative ELISA-based test where 4 ... each well of a 96-well plate in ...
The strip cap tool is a used for properly seating 8- and 12-cap strips in microplates or strip tubes. A grooved channel on one side is designed to seat domed caps, while the flat edge on the opposite...
... The expertise that made the original Gene Pulser ... system available has been applied in the Gene ... The modular design of the Gene Pulser II ... accessory that has the widest range of settings ...
Biology Products: